08:00 , Jan 8, 2015 |  BC Innovations  |  Translation in Brief

Uptick for Lyme vaccine

Commercial interest in Lyme disease has all but ground to a halt since the withdrawal of the first vaccine, Lymerix, more than a decade ago, despite a tenfold increase in the U.S. incidence of the...
07:00 , Oct 1, 2009 |  BC Innovations  |  Cover Story

Targeting the TB proteasome

Researchers at Weill Cornell Medical College have identified compounds that can kill non-replicating Mycobacterium by selectively and irreversibly inhibiting the organism's proteasome. 1 Beyond the potential for new therapeutics for tuberculosis, the findings provide a...
07:00 , Sep 24, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Tuberculosis (TB) Mycobacterium tuberculosis proteasome A study in cell culture identified oxathiazol-2-one M. tuberculosis proteasome inhibitors that could help treat TB. Dialysis and kinetics...
08:00 , Feb 7, 2008 |  BC Innovations  |  Tools & Techniques

Live imaging of NPCs

Noninvasive imaging of neuronal progenitor cells in the live human brain has been impossible because of the shortcomings of existing imaging methods, specifically the toxicity of PET and the low sensitivity associated with MRI. A...
07:00 , Jul 16, 2007 |  BioCentury  |  Product Development

Down-sizing the high

Since agonizing gamma-aminobutyric acid receptors has been shown to decrease dopamine in the brain, GABA receptors are a target for therapeutics to treat substance abuse. However, compounds that directly agonize the receptors have drawbacks that...
08:00 , Jan 13, 2003 |  BC Week In Review  |  Company News

BioSurface Engineering Technologies Inc., U.S. Department of Energy’s Brookhaven National Laboratory deal

BioSurface received exclusive worldwide rights to synthetic analogs of two growth factors, including fibroblast growth factor (FGF) , for wound healing and radiation protection. The analogs were developed under a collaboration between BioSurface and the...
07:00 , Aug 13, 2001 |  BC Week In Review  |  Company News

BTG, Brookhaven National Laboratory deal

BTG will provide technology transfer functions for Brookhaven’s life sciences and physical sciences departments. BTG plc (LSE:BCG), London, U.K.   Brookhaven National Laboratory , Upton, N.Y.   Business: Other  ...
08:00 , Mar 13, 2000 |  BC Week In Review  |  Company News

Dow AgroSciences, Dow Chemical deal

The companies will form the Oilseed Engineering Alliance to collaborate with Michigan State University, Miami University, Washington State University, and Brookhaven National Laboratory to develop improved traits in soybeans and other crops for use as...
08:00 , Mar 9, 2000 |  BC Extra  |  Company News

Oilseed Engineering Alliance formed

Dow Chemical , Dow AgroSciences , Michigan State University, Miami University, Washington State University and the U.S. Department of Energy's Brookhaven National Laboratory formed the Oilseed Engineering Alliance, which will develop soybeans and other crops...
07:00 , Jun 28, 1999 |  BC Week In Review  |  Company News

Diatide other research news

Under a CRADA, DITI and Brookhaven National Laboratory will develop Stanamet as a bone cancer treatment. Brookhaven received a $750,000 grant over three years from the Department of Energy to develop the therapy. DITI exclusively...